There is one clinical trial.
Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients. Infection with SARS-CoV-2 causes human COVID-19 (HCoV-19). The infection is associated with a deleterious inflammatory response and a prothrombotic state in addition to tissue damage from direct viral entry and proliferation. Dipyridamole has anti-platelet and anti-inflammatory effects. The drug was recently demonstrated to have anti-SARS-Cov-2 effect primarily in vitro. The concentration causing anti-viral effect in vitro is within that in the blood of humans taking this drug. As an oral tablet, it has the advantage of easy administration. Anti thrombotic, anti viral and anti inflammatory actions of this drug may be efficacious and safe in hospitalized subjects
Description: D-dimer and platelet countMeasure: Coagulation system Time: 9 days
Description: Evaluate for a non-detection from nasopharyngeal swab and in stoolMeasure: Viral Detection Time: 9 days
Description: Survival Status AliveMeasure: Survival Time: 9 days
Description: Change in the markers CRP/FerritinMeasure: Inflammatory Markers Time: 9 days
Description: Change in Lymphocyte Count/ Fibrinogen/Cardiac TroponinMeasure: Blood Markers Time: 9 days
Description: Change in PT, PTTMeasure: Coagulation Markers Time: 9 days
Description: Change in SpO2/ imagingMeasure: Pulmonary Status Time: 9 days
Description: Change in fever, cough, sputumMeasure: Clinical Status Time: 9 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports